Taysha Gene Therapies Inc. (NASDAQ:TSHA) finished Wednesday with an addition of $0.23 to close at $2.22, an upside of 11.56 percent. An average of 2,458,440 shares of common stock have been traded in the last five days. There was a gain of $0.2900 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 10,918,835 shares traded, while the 50-day average volume stands at 4,526,066.
TSHA stock has increased by 231.34% in the last month. The company shares reached their 1-month lowest point of $0.6200 on 07/27/23. With the stock rallying to its 52-week high on 08/15/23, shares of the company touched a low of $0.50 and a high of $4.06 in 52 weeks. It has reached a new high 3 times so far this year and lost -1.77% or -$0.0400 in price. In spite of this, the price is down -45.29% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
TSHA stock investors should be aware that Taysha Gene Therapies Inc. (TSHA) stock had its last reported insider trading activity 42 days ago on Aug 16. In this transaction, the insider spent $3,741. 10% Owner, Session R.A. II, disposed of 80,528 shares at a price of $0.71 on Jul 12. The insider now owns more than $57,030 worth of shares. Prior to that, 10% Owner Session R.A. II went on to Sale 18,100 shares at $0.70 each on Jun 23. An amount of $12,735 was transacted.
Valuation Metrics
Taysha Gene Therapies Inc. (TSHA) stock’s beta is -0.04. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 14.60.
Financial Health
The quick ratio of Taysha Gene Therapies Inc. for the three months ended June 29 was 1.10, and the current ratio was 1.10, indicating that the company is able to meet its debt obligations. Taysha Gene Therapies Inc.’s EBITDA margin for the year ending June 29 is -4937.65%. Its gross profit as reported stood at $164.95 million compared to revenue of $2.5 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Taysha Gene Therapies Inc.’s return on assets was -118.10%.
Earnings Surprise
For the three-month period that ended June 29, Taysha Gene Therapies Inc. had $38.35 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$24.6 million in the quarter, while revenues of -$17.62 million were shrunk -37.68%. The analyst consensus anticipated Taysha Gene Therapies Inc.’s latest quarter earnings to come in at -$0.31 per share, but it turned out to be -$0.38, a -22.60% surprise. For the quarter, EBITDA amounted to -$23.04 million. Shareholders own equity worth $64.47 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Taysha Gene Therapies Inc. (TSHA) price momentum. RSI 9-day as of the close on 23 August was 83.31%, suggesting the stock is Overbought, with historical volatility in this time frame at 525.06%.
As of today, TSHA’s price is $1.9900 +15.03% or $0.2900 from its 5-day moving average. TSHA is currently trading +242.86% higher than its 20-day SMA and +206.63% higher than its 100-day SMA. However, the stock’s current price level is +169.09% above the SMA50 and +13.85% above the SMA200.
The stochastic %K and %D were 75.94% and 71.70%, respectively, and the average true range (ATR) was 0.2600. With the 14-day stochastic at 85.53% and the average true range at 0.2200, the RSI (14) stands at 81.99%. The stock has reached 0.1600 on the 9-day MACD Oscillator while the 14-day reading was at 0.5800.
Analyst Ratings
Jefferies downgraded Taysha Gene Therapies Inc. (NASDAQ: TSHA) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Taysha Gene Therapies Inc. (TSHA) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TSHA, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 7 others rate it as a “buy”.
What is TSHA’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $8.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for Taysha Gene Therapies Inc. (TSHA) stock is $5.72.
